Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim completes trial enrolment

Boehringer Ingelheim completes trial enrolment

18th January 2008

Enrolment is now complete for a trial involving oral direct thrombin inhibitor dabigtran etexilate, Boehringer Ingelheim announced on Thursday.

The Randomised Evaluation of Long Term Anticoagulant Therapy (Re-Ly) study aims to assess the efficacy and safety over a long-term period of the treatment for systemic embolism and stroke in patients affected with atrial fibrillation.

Some 18,114 patients have taken part in the trial so far, Boehringer Ingelheim explained, across 44 countries between December 2005 and December 2007.

The study uses two blind doses of oral dabigtran etexilate combined with warfarin sodium to compare the effects in patients who have a moderate to high risk of stroke.

It is reported that although warfarin is the standard treatment for the prevention of stroke in those with non-valvular atrial fibrillation, it is currently prescribed for about half of elegible subjects.

“Our investment in landmark trials such as Re-Ly demonstrates Boehringer Ingelheim’s ongoing commitment to improving future treatment options for patients with cardiovascular conditions,” remarked Dr Andreas Barner, a member of the firm’s board. Dr Barner is also responsible for its research, development and medicine.

Boehringer Ingelheim published study results last month for its Inspire research, which aimed to discover the relative efficacy of certain medicines for chronic obstructive pulmonary disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.